Literature DB >> 30014109

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease.

Noha Abdel-Wahab1, Mohsin Shah1, Maria A Lopez-Olivo1, Maria E Suarez-Almazor1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30014109     DOI： 10.7326/L18-0209

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  13 in total

1.  Scleroderma-like syndrome associated with pembrolizumab.

Authors:  Silvia Suárez-Díaz; Rubén Coto-Hernández; Carmen Yllera-Gutiérrez; Carlos Álvarez-Fernández; Luis Trapiella-Martínez; Luis Caminal-Montero
Journal:  J Scleroderma Relat Disord       Date:  2020-02-18

Review 2.  Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors.

Authors:  Benjamin C Park; Seungyeon Jung; Steven T Chen; Anna K Dewan; Douglas B Johnson
Journal:  Am J Clin Dermatol       Date:  2022-06-16       Impact factor: 6.233

Review 3.  Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.

Authors:  Arielle L Heeke; Antoinette R Tan
Journal:  Cancer Metastasis Rev       Date:  2021-06-08       Impact factor: 9.237

4.  Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake.

Authors:  Takatsugu Ogata; Yukiya Narita; Kazunari Misawa; Waki Hosoda; Kei Muro
Journal:  Clin Case Rep       Date:  2020-11-18

Review 5.  Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases.

Authors:  Tomasz Kubiatowski; Marcin Nicoś; Paweł Krawczyk
Journal:  Front Oncol       Date:  2020-11-19       Impact factor: 6.244

6.  Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.

Authors:  Maen Abdelrahim; Omar Mamlouk; Heather Lin; Jamie Lin; Valda Page; Noha Abdel-Wahab; Joshua Swan; Umut Selamet; Cassian Yee; Adi Diab; Wadi Suki; Ala Abudayyeh
Journal:  Oncoimmunology       Date:  2021-05-23       Impact factor: 8.110

Review 7.  Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction.

Authors:  Vaia Florou; Sonam Puri; Ignacio Garrido-Laguna; Breelyn A Wilky
Journal:  Ann Transl Med       Date:  2021-06

8.  Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis.

Authors:  Elizaveta Efuni; Samuel Cytryn; Patrick Boland; Timothy B Niewold; Anna Pavlick; Jeffrey Weber; Sabina Sandigursky
Journal:  J Clin Rheumatol       Date:  2021-10-01       Impact factor: 3.902

Review 9.  Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.

Authors:  Vickie R Shannon; Ronald Anderson; Ada Blidner; Jennifer Choi; Tim Cooksley; Michael Dougan; Ilya Glezerman; Pamela Ginex; Monica Girotra; Dipti Gupta; Douglas B Johnson; Maria E Suarez-Almazor; Bernardo L Rapoport
Journal:  Support Care Cancer       Date:  2020-09-03       Impact factor: 3.603

Review 10.  International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.

Authors:  Pushpa Narayanaswami; Donald B Sanders; Gil Wolfe; Michael Benatar; Gabriel Cea; Amelia Evoli; Nils Erik Gilhus; Isabel Illa; Nancy L Kuntz; Janice Massey; Arthur Melms; Hiroyuki Murai; Michael Nicolle; Jacqueline Palace; David Richman; Jan Verschuuren
Journal:  Neurology       Date:  2020-11-03       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.